Please wait while the formulary information is being retrieved.
Drug overview for POLYCIN (bacitracin/polymyxin b sulfate):
Generic name: bacitracin/polymyxin B sulfate (BAS-i-TRAY-sin/POL-ee-MIX-in)
Drug class: Ophthalmic Antibacterials
Therapeutic class: Ophthalmic Agents
Bacitracin is a polypeptide antibiotic. Polymyxin B is a polymyxin antibiotic.
No enhanced Uses information available for this drug.
Generic name: bacitracin/polymyxin B sulfate (BAS-i-TRAY-sin/POL-ee-MIX-in)
Drug class: Ophthalmic Antibacterials
Therapeutic class: Ophthalmic Agents
Bacitracin is a polypeptide antibiotic. Polymyxin B is a polymyxin antibiotic.
No enhanced Uses information available for this drug.
DRUG IMAGES
- POLYCIN EYE OINTMENT
The following indications for POLYCIN (bacitracin/polymyxin b sulfate) have been approved by the FDA:
Indications:
Superficial ocular infection
Professional Synonyms:
Superficial ophthalmic infection
Indications:
Superficial ocular infection
Professional Synonyms:
Superficial ophthalmic infection
The following dosing information is available for POLYCIN (bacitracin/polymyxin b sulfate):
Dosage of bacitracin or bacitracin zinc is expressed in terms of the base.
Potency and dosage of polymyxin B sulfate are expressed in terms of polymyxin B activity (units of polymyxin B).
Potency and dosage of polymyxin B sulfate are expressed in terms of polymyxin B activity (units of polymyxin B).
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for POLYCIN (bacitracin/polymyxin b sulfate):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for POLYCIN (bacitracin/polymyxin b sulfate):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 0 severe contraindications.
There are 1 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
Moderate List |
---|
No disease contraindications |
The following adverse reaction information is available for POLYCIN (bacitracin/polymyxin b sulfate):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 9 severe adverse reactions.
More Frequent | Less Frequent |
---|---|
Ocular inflammation Ocular itching Ocular redness |
Ocular irritation |
Rare/Very Rare |
---|
Anaphylaxis Apnea Chest tightness Facial edema Hypotension |
There are 6 less severe adverse reactions.
More Frequent | Less Frequent |
---|---|
None. | None. |
Rare/Very Rare |
---|
Candidiasis Conjunctival hyperemia Hyperhidrosis Ocular irritation Ocular itching Skin rash |
The following precautions are available for POLYCIN (bacitracin/polymyxin b sulfate):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
None |
Severe Precaution
None |
Management or Monitoring Precaution
None |
Animal reproduction studies have not been performed with bacitracin. It is not known whether ophthalmic preparations containing bacitracin or bacitracin zinc can cause fetal harm when administered to pregnant women. Fixed-combination ophthalmic preparations containing bacitracin zinc and polymyxin B sulfate with or without neomycin sulfate should be used during pregnancy only if clearly needed.
Fixed-combination ophthalmic preparations containing bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and a corticosteroid (i.e., hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Animal reproduction studies have not been performed with polymyxin B sulfate. It is not known whether ophthalmic preparations containing polymyxin B sulfate can cause fetal harm when administered to pregnant women.
Fixed-combination ophthalmic preparations of polymyxin B sulfate and bacitracin zinc or polymyxin B sulfate, neomycin sulfate, and either bacitracin zinc or gramicidin should be used during pregnancy only if clearly needed. Because trimethoprim may interfere with folic acid metabolism, fixed-combination ophthalmic preparations containing polymyxin B sulfate and trimethoprim sulfate should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, other anti-infectives (i.e., neomycin sulfate, bacitracin zinc), and a corticosteroid (i.e., dexamethasone, hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used during pregnancy only if potential benefits justify potential risks to the fetus.
Fixed-combination ophthalmic preparations containing bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and a corticosteroid (i.e., hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Animal reproduction studies have not been performed with polymyxin B sulfate. It is not known whether ophthalmic preparations containing polymyxin B sulfate can cause fetal harm when administered to pregnant women.
Fixed-combination ophthalmic preparations of polymyxin B sulfate and bacitracin zinc or polymyxin B sulfate, neomycin sulfate, and either bacitracin zinc or gramicidin should be used during pregnancy only if clearly needed. Because trimethoprim may interfere with folic acid metabolism, fixed-combination ophthalmic preparations containing polymyxin B sulfate and trimethoprim sulfate should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, other anti-infectives (i.e., neomycin sulfate, bacitracin zinc), and a corticosteroid (i.e., dexamethasone, hydrocortisone, hydrocortisone acetate) should be used during pregnancy only if potential benefits justify potential risks to the fetus. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used during pregnancy only if potential benefits justify potential risks to the fetus.
It is not know whether bacitracin is distributed into milk. Bacitracin and fixed-combination ophthalmic preparations containing bacitracin zinc and polymyxin B sulfate with or without neomycin sulfate should be used with caution in nursing women. The manufacturers of fixed-combination ophthalmic preparations containing bacitracin zinc, neomycin sulfate, polymyxin B sulfate, and a corticosteroid (i.e., hydrocortisone, hydrocortisone acetate) state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman.
Some experts consider topical bacitracin compatible with nursing. Fixed-combination ophthalmic preparations containing polymyxin B sulfate and other anti-infectives (i.e., bacitracin zinc, gramicidin, neomycin sulfate, trimethoprim sulfate) should be used with caution in nursing women. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, and dexamethasone should be used with caution in nursing women.
The manufacturers of fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, bacitracin zinc, and hydrocortisone or hydrocortisone acetate state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used with caution in nursing women.
Some experts consider topical bacitracin compatible with nursing. Fixed-combination ophthalmic preparations containing polymyxin B sulfate and other anti-infectives (i.e., bacitracin zinc, gramicidin, neomycin sulfate, trimethoprim sulfate) should be used with caution in nursing women. Fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, and dexamethasone should be used with caution in nursing women.
The manufacturers of fixed-combination ophthalmic preparations containing polymyxin B sulfate, neomycin sulfate, bacitracin zinc, and hydrocortisone or hydrocortisone acetate state that a decision should be made whether to discontinue nursing or the ophthalmic preparation, taking into account the importance of the drug to the woman. Fixed-combination otic preparations containing polymyxin B sulfate, neomycin sulfate, and hydrocortisone should be used with caution in nursing women.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for POLYCIN (bacitracin/polymyxin b sulfate):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for POLYCIN (bacitracin/polymyxin b sulfate)'s list of indications:
Superficial ocular infection | |
H10.0 | Mucopurulent conjunctivitis |
H10.01 | Acute follicular conjunctivitis |
H10.011 | Acute follicular conjunctivitis, right eye |
H10.012 | Acute follicular conjunctivitis, left eye |
H10.013 | Acute follicular conjunctivitis, bilateral |
H10.019 | Acute follicular conjunctivitis, unspecified eye |
H10.02 | Other mucopurulent conjunctivitis |
H10.021 | Other mucopurulent conjunctivitis, right eye |
H10.022 | Other mucopurulent conjunctivitis, left eye |
H10.023 | Other mucopurulent conjunctivitis, bilateral |
H10.029 | Other mucopurulent conjunctivitis, unspecified eye |
Formulary Reference Tool